Abstract:BackgroundCurrent primary prevention guidelines for cardiovascular disease (CVD) prioritize risk identification, risk stratification using clinical and risk scores, and risk reduction with lifestyle interventions and pharmacotherapy. Subclinical atherosclerosis is an early indicator of atherosclerotic burden and its timely recognition can slow or prevent progression to CVD. Thus, individuals with subclinical atherosclerosis are a priority for primary prevention. This study takes a practical approach to answering a challenge commonly faced by primary care practitioners: in patients with no known CVD, how can individuals likely to have subclinical atherosclerosis be easily identified using existing clinical data and/or information provided by the patient?MethodsUsing NHANES (1999–2004), 6091 men and women aged ≥40 years without any CVD comprised the primary prevention population for this study. Subclinical atherosclerosis was determined via ankle-brachial index (ABI) using established cutoffs (subclinical atherosclerosis defined as ABI (0.91–0.99); normal defined as ABI (1.00–1.30)). Three common scores were calculated: the Framingham Risk Score (FRS), the Metabolic Syndrome (MetS), and the Cardiovascular Health Index (CVHI). Logistic regression analysis assessed the association between these scores and subclinical atherosclerosis. The sensitively and specificity of these scores in identifying subclinical atherosclerosis was determined.ResultsIn eligible participants, 3.8% had subclinical atherosclerosis. Optimum and average CVHI was associated with decreased odds for subclinical atherosclerosis. High, but not intermediate-risk, FRS was associated with increased odds for subclinical atherosclerosis. MetS was not associated with subclinical atherosclerosis. Of the 3 scores, CVHI was the most sensitive in identifying subclinical atherosclerosis and had the lowest number of missed cases. The FRS was the most specific but least sensitive of the 3 scores, and had almost 10-fold more missed cases vs. the CVHI. The MetS had “middle” sensitivity and specificity, and 10-fold more missed cases vs. the CVHI.ConclusionsResults from this study suggest that routine administration of the CVHI in a primary prevention population would yield the benefits of identifying patients with existing subclinical CVD not identified through traditional CVD risk factors or scores, and bring physical activity and nutrition to the forefront of provider-patient discussions about lifestyle factors critical to maintaining and prolonging cardiovascular health.

Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications

Personalizing Treatment: Between Primary and Secondary Prevention

Advancements in risk stratification and management strategies in primary cardiovascular prevention

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease

Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review

Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?

Management of vulnerable patient phenotypes and acute coronary syndrome mechanisms

Coronary artery anomalies: what we know and what we have to learn. A proposal for a new clinical classification.

Intravascular molecular imaging: translating pathophysiology of atherosclerosis into human disease conditions

The clinical relevance of the reversal of coronary atherosclerotic plaque

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events

Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach

Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future

Residual risks and evolving atherosclerotic plaques

Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

Re-Evaluation of Cardiovascular Disease Risk and Primary Prevention Treatments with Coronary Artery Calcium Scoring in Primary Prevention Patients

Assessment of Subclinical Atherosclerosis in Asymptomatic People In Vivo: Measurements Suitable for Biomarker and Mendelian Randomization Studies

Coronary CT Angiography Guided Medical Therapy in Subclinical Atherosclerosis